Amgen price hikes to offset Aranesp payment drop

A new Medicare payment scheme for dialysis will likely result in a revenue drop for Amgen from its kidney disease treatment Aranesp. To compensate, the drugmaker has raised prices on several drugs.

Aranesp itself gets a 4.4 percent boost, reports Bloomberg. Prices on chemo-effect treatments Neulasta and Neupogen jump 2.9 percent.

Medicare cost controls have yielded a new payment scheme for dialysis treatment. In addition, Amgen suffered a 15 percent drop in sales of Aranesp in 2009, according to the report.

- here's the story

Suggested Articles

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.